DERMATOP
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DERMATOP (DERMATOP).
Prednicarbate is a corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of arachidonic acid from membrane phospholipids.
| Metabolism | Prednicarbate is metabolized primarily in the skin via hydrolysis to inactive metabolites; systemic metabolism follows pathways typical of corticosteroids. |
| Excretion | Primarily hepatic metabolism with inactive metabolites; <10% excreted renally as unchanged drug; minimal biliary/fecal elimination. |
| Half-life | Terminal elimination half-life: approximately 100 hours (range 68-120 hours) following topical administration; prolonged accumulation with chronic use due to high lipophilicity and slow release from skin depot. |
| Protein binding | Prednisolone (active metabolite) is 70-90% bound to albumin and corticosteroid-binding globulin (CBG); prednicarbate itself is highly protein-bound (>95%). |
| Volume of Distribution | Apparent Vd: Not well characterized for topical route; for systemic corticosteroids, Vd is approximately 0.5-1.0 L/kg, indicating extensive tissue distribution; clinical meaning: large Vd reflects high lipophilicity and tissue uptake. |
| Bioavailability | Topical: Percutaneous absorption 1-5% in normal skin; increased to 10-30% in inflamed or damaged skin; systemic bioavailability is minimal with intact skin but can be significant with occlusive dressings or widespread use. |
| Onset of Action | Topical: Improvement noted within 1-2 weeks of regular application; maximal effect by 3-4 weeks. |
| Duration of Action | Duration: Sustained anti-inflammatory effect persists for several days to weeks after discontinuation due to skin reservoir; clinical remission may last weeks to months. |
Apply a thin layer to affected skin areas twice daily (morning and evening) for up to 4 weeks. Do not use more than 50 g per week.
| Dosage form | OINTMENT |
| Renal impairment | No dose adjustment required for renal impairment; topical application results in negligible systemic absorption. |
| Liver impairment | No specific dose adjustment guidelines available; use caution in severe hepatic impairment due to potential systemic effects. |
| Pediatric use | For children ≥2 years: Apply a thin layer to affected areas twice daily; maximum treatment duration is 4 weeks. Avoid use in children <2 years due to increased risk of systemic absorption. |
| Geriatric use | No specific dose adjustment; use the lowest effective dose for the shortest duration due to increased skin fragility and potential for systemic absorption. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DERMATOP (DERMATOP).
| Breastfeeding | Prednisolone is excreted into breast milk in low concentrations. M/P ratio is approximately 0.4-0.8 for prednisolone. Maternal doses up to 40 mg/day are considered compatible with breastfeeding. Monitor infant for signs of adrenal suppression. |
| Teratogenic Risk | FDA Pregnancy Category C. Prednisolone is a corticosteroid; animal studies show increased risk of cleft palate at high doses. First-trimester exposure may be associated with a small increased risk of oral clefts. Chronic use in second/third trimester may cause fetal adrenal suppression. Limited human data; benefit must outweigh risk. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to prednicarbate or any component of the formulation"]
| Precautions | ["Systemic absorption may cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression","Cushing's syndrome, hyperglycemia, and glucosuria may occur with extensive use","Local irritation, atrophy, and allergic contact dermatitis may develop","Use in children should be limited to the smallest amount necessary due to increased susceptibility to systemic effects"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, blood glucose, serum electrolytes, and signs of infection. Fetal monitoring includes ultrasound for growth restriction if chronic use. Assess fetal adrenal function if maternal use prolonged near term. |
| Fertility Effects | Corticosteroids may suppress hypothalamic-pituitary-adrenal axis, potentially causing menstrual irregularities and impaired fertility. Effects are reversible upon dose reduction or discontinuation. |